NEW YORK — BioRewards Plasma Services, a new entrant in the plasma collection industry, has officially launched with the support of Alpha-1 Plasma Holdings in a bold $100 million expansion initiative aimed at revolutionizing how plasma is collected, processed, and delivered. Over the next three years, the company plans to open more than 20 advanced plasma collection centers across the United States, with additional international locations already in the planning phase.
Backed by equity investments and debt financing, BioRewards is positioning itself as a next-generation plasma collection provider focused on improving the donor experience, embracing advanced digital technologies, and meeting the growing global demand for plasma-derived medicinal products (PDMPs).
“Our mission is simple but critical—to provide a flexible and modern approach to plasma collection that meets the growing demand for plasma-derived medicines,” said Chris Barber, Chief Operating Officer of BioRewards. “Our leadership team brings decades of industry experience and understands what it takes to scale effectively while maintaining the highest standards of quality.”
At the heart of BioRewards’ approach is a technology-driven operational model. The company is deploying AI-powered site selection tools, CRM-based donor engagement platforms, and data-driven systems to optimize workflow, reduce donor wait times, and improve collection efficiency. BioRewards will collect both normal source and hyperimmune plasma, which are essential raw materials for producing life-saving therapies for a wide range of conditions.
Charles Auger, CEO of BioRewards, highlighted the company’s commitment to working closely with plasma fractionators worldwide. “Our ability to collaborate creatively with PDMP fractionators globally, combined with our relentless focus on innovation and efficiency, makes us a partner of choice in this industry,” he said.
Alpha-1 Plasma Holdings, the primary backer of the initiative, sees BioRewards as a much-needed disruptor in the evolving plasma market. “The independent plasma sector needs forward-thinking companies that can reliably and cost-effectively meet global plasma demand,” said John Fontana, CEO of Alpha-1. “BioRewards combines vision, strategy, execution, and the ability to form critical financial and real estate partnerships—all of which position it for long-term success.”
The expansion comes at a critical time for the plasma industry, as global demand for PDMPs continues to rise. BioRewards is already drawing early interest from international plasma fractionators and healthcare partners, signaling strong market confidence in its model.
Peter M. Jaworski, Ph.D., a senior advisor at Alpha-1, underscored the broader impact of the effort. “Plasma-derived therapies are essential to millions of patients worldwide,” he said. “BioRewards will increase the high-quality plasma supply necessary to meet growing demand in a sustainable and scalable way.”
As BioRewards begins its expansion across the U.S. and beyond, the company is seeking to collaborate with global fractionators, healthcare providers, and local communities to shape the future of plasma collection and delivery.
